CLINICAL TRIALS PROFILE FOR EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

505(b)(2) Clinical Trials for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00641641 ↗	The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection	Completed	Merck Sharp & Dohme Corp.	N/A	2008-03-01	The purpose of this study is to measure the decay characteristics of HIV in the blood of patients after taking a combination of anti-HIV drugs, which includes a new class of anti-HIV drug, an integrase inhibitor. This study explores how this new combination of therapy reduces virus in various compartments of the body and immune system.
New Combination	NCT00641641 ↗	The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection	Completed	Kirby Institute	N/A	2008-03-01	The purpose of this study is to measure the decay characteristics of HIV in the blood of patients after taking a combination of anti-HIV drugs, which includes a new class of anti-HIV drug, an integrase inhibitor. This study explores how this new combination of therapy reduces virus in various compartments of the body and immune system.
New Formulation	NCT02583464 ↗	Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.	Completed	Laboratorio Elea Phoenix S.A.	Phase 1	2014-09-01	Objective: To evaluate the relative bioavailability of a new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) and compare this formulation with the branded formulation (R) to meet regulatory criteria for marketing the test product in Argentina.
New Formulation	NCT02583464 ↗	Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.	Completed	Laboratorio Elea S.A.C.I.F. y A.	Phase 1	2014-09-01	Objective: To evaluate the relative bioavailability of a new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) and compare this formulation with the branded formulation (R) to meet regulatory criteria for marketing the test product in Argentina.

All Clinical Trials for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	PENTA Foundation	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00051831 ↗	Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults	Completed	AIDS Clinical Trials Group	N/A	2003-10-01	HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called a fusion inhibitor. The purpose of this study is to test the ability of a T-20-enhanced treatment regimen to decrease the number of resting CD4 cells that become infected with HIV.
NCT00051831 ↗	Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	2003-10-01	HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called a fusion inhibitor. The purpose of this study is to test the ability of a T-20-enhanced treatment regimen to decrease the number of resting CD4 cells that become infected with HIV.
NCT00055120 ↗	When to Start Anti-HIV Drugs in Patients With Opportunistic Infections	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4	2003-03-01	The purpose of this study is to evaluate the effect of starting anti-HIV drugs in HIV infected patients who are being treated for opportunistic infections (OIs). This study will follow two patient groups: those who received anti-HIV drugs soon after being diagnosed with an OI and patients with OIs who deferred beginning anti-HIV drugs until after recovering from the OI.

Clinical Trial Conditions for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Condition Name

Condition Name for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Intervention	Trials
HIV Infections	67
HIV	27
HIV-1 Infection	18
HIV Infection	13

Condition MeSH

Condition MeSH for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Intervention	Trials
HIV Infections	104
Acquired Immunodeficiency Syndrome	44
Infections	25
Immunologic Deficiency Syndromes	24

Clinical Trial Locations for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Trials by Country

Trials by Country for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Location	Trials
United States	909
Canada	86
Spain	52
United Kingdom	48
South Africa	45

Trials by US State

Trials by US State for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Location	Trials
California	67
New York	51
Florida	51
Texas	48
North Carolina	47

Clinical Trial Progress for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Clinical Trial Phase

Clinical Trial Phase for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	4

Clinical Trial Status

Clinical Trial Status for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Clinical Trial Phase	Trials
Completed	131
Recruiting	14
Active, not recruiting	12

Clinical Trial Sponsors for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Sponsor Name

Sponsor Name for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Sponsor	Trials
Gilead Sciences	71
National Institute of Allergy and Infectious Diseases (NIAID)	46
AIDS Clinical Trials Group	12

Sponsor Type

Sponsor Type for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Sponsor	Trials
Other	180
Industry	121
NIH	60

Emtricitabine + Tenofovir Disoproxil Fumarate (FTC/TDF): Clinical Trial Update, Market Analysis, and Forward Projections

Last updated: May 9, 2026

What is FTC/TDF and where is it positioned clinically?

Emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) is an oral, fixed-dose antiretroviral backbone used for HIV treatment and HIV prevention (PrEP). Commercially, FTC/TDF is delivered via multiple branded and generic fixed-dose combinations (FDCs) and is widely used across guideline-based care pathways.

Core use cases

• HIV treatment (combination ART): FTC/TDF forms part of standard nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbones in ART regimens.
• HIV prevention (PrEP): FTC/TDF is a first-line option in multiple guideline frameworks for ongoing HIV risk reduction.

Key clinical context

• FTC/TDF competes in prevention against long-acting and newer NRTI backbones (notably TAF-based options and long-acting injectable strategies in some markets).
• In treatment, FTC/TDF remains entrenched in settings where cost, formulary position, and regimen simplicity drive adoption.

What do the clinical trials pipeline signals imply for FTC/TDF through the next cycle?

No single current phase program dominates the FTC/TDF narrative because the drug combination is mature and widely generic. Clinical activity has shifted toward:

• Comparative effectiveness and implementation studies (adherence, dosing strategies, real-world outcomes)
• Special population studies (co-morbidities, renal safety monitoring strategies, pregnancy-related outcomes)
• PrEP persistence and switching evaluations (including transitions between TDF and TAF-based regimens where available)
• Regimen optimization (non-inferiority studies in specific subgroups or in new treatment combinations)

Because FTC/TDF is an established therapy, most ongoing “trial” activity is not about inventing a new MOA. The practical question for investors and R&D leads is market share risk: whether alternative backbones and delivery formats take share fast enough to pressure volumes and pricing.

Pipeline structure seen in mature antiretrovirals

For matured backbone combinations like FTC/TDF, trial volume typically splits into:

• PrEP optimization (real-world and phase studies): adherence and discontinuation patterns; drug-drug interaction checks in co-medicated populations.
• Safety-driven studies: renal function endpoints and monitoring cadence; bone mineral density endpoints in prevention use and in longer treatment durations.
• Access and guideline alignment studies: outcomes tied to implementation in public systems and formularies.

Implications for development strategy

• There is limited upside from new efficacy signals for FTC/TDF itself because effect size is already established.
• The primary value is in lifecycle management: maintaining guideline inclusion, formulary placement, and patient persistence in prevention programs.

Where does FTC/TDF face regulatory and payer pressure?

The main pressure points come from competition and shifting preference:

Competition by backbone and formulation

• Tenofovir alafenamide (TAF)-based PrEP and treatment regimens: often preferred for renal and bone outcomes in some jurisdictions.
• Long-acting PrEP approaches: where adopted, they structurally reduce reliance on daily oral PrEP.

Payer logic that governs utilization

• Total cost and formulary rules: FTC/TDF often retains access when pricing is lowest and inventory is stable.
• Safety monitoring costs: payers and programs account for renal monitoring and patient monitoring burden; if TAF reduces monitoring intensity, switching can occur in higher-income markets and in private insurance plans.

What is the market size and trajectory for FTC/TDF?

FTC/TDF is one of the largest-volume HIV medicines globally due to broad use in treatment and wide adoption in prevention. Market expansion is constrained by:

• Mature treatment markets with slower growth
• Prevention competition from TAF-based regimens and alternative PrEP strategies
• Ongoing generics erosion on price

Market drivers supporting demand

• High HIV prevalence and ongoing diagnosis rates maintain base demand.
• PrEP programs in many regions continue scaling, with FTC/TDF historically a default due to cost and ease of procurement.
• Generics sustain affordability for public procurement and high-volume patient programs.

Market drag factors

• Uptake of TAF-based alternatives where formularies permit.
• Long-acting prevention options in markets where guideline adoption accelerates.
• Program-level switching triggered by safety monitoring costs and patient preference.

How do price and competition dynamics shape projections?

FTC/TDF is priced under intense generic competition. Projections should treat volume as the main lever, with pricing likely to remain under downward pressure.

Competitive landscape

• Brand vs generic: most mature markets rely on generics; price compression is structural.
• Backbone substitution risk: the main competitive threat is not another molecule with the same MOA; it is switching within tenofovir-based prevention and treatment options.

Projection logic for a mature combination

• Units: grow modestly with ongoing prevention scaling and stable treatment retention.
• Revenue: grows slower than units (often flat to low single-digit) because ASP declines and contract tender cycles drive price resets.

What does a practical 3- to 5-year projection look like?

Below is a business-grade projection framework anchored to how mature HIV backbones behave: unit growth driven by prevention expansion, tempered by TAF and alternate prevention, and revenue diluted by generic price declines.

Base case projection framework (directional)

• 2026-2028: modest unit growth; revenue flat to low growth due to continued price erosion and periodic contract renegotiation.
• 2029-2031: unit growth slows further as backbone switching and alternative prevention options mature in certain geographies; revenue likely remains flat or declines low single-digits absent new procurement shocks.

Scenario bands

Scenario	Unit trajectory	Revenue trajectory	Primary driver
Base case	Low to mid single-digit CAGR	Flat to low single-digit CAGR	Continued prevention scaling with persistent generic competition
Bull case	Higher low double-digit unit CAGR	Low single-digit revenue CAGR	Faster PrEP uptake and continued guideline preference for TDF-based prevention in cost-sensitive markets
Bear case	Low single-digit unit CAGR	Flat to low single-digit decline	Accelerated switching to TAF-based PrEP and faster adoption of non-daily prevention in key markets

Where are the biggest market inflection points for FTC/TDF?

1. PrEP guideline and formulary outcomes in large procurement regions.
2. TAF substitution rates in insured and private-market populations.
3. Program adherence and persistence metrics in prevention use, which directly determine per-patient usage duration.
4. Renal safety monitoring costs and whether payer policies incentivize switching.

What are the patent and exclusivity implications for FTC/TDF market shares?

Because FTC/TDF is mature and widely generic, the patent landscape does not typically create new monetization windows for the original combination product at this stage. Market share is primarily determined by:

• Tender outcomes (lowest-cost procurement)
• Brand-to-generic switching in treatment
• Prevention program contracts

For investors evaluating “FTC/TDF opportunity,” the realistic lever is procurement positioning, not patent-driven differentiation.

Key product and commercial considerations for execution

Commercial execution

• Maintain competitive tender readiness for public procurement channels where FTC/TDF is price dominant.
• Optimize manufacturing and supply continuity to avoid procurement losses due to stock-outs.

R&D execution (limited but non-zero)

• Focus on lifecycle and outcomes work tied to persistence, safety monitoring protocols, and implementation in high-burden settings.
• If pursuing new evidence packages, prioritize payer-relevant endpoints: renal safety monitoring cadence, adherence impacts, and program continuation.

Key Takeaways

• FTC/TDF remains a cornerstone HIV treatment and prevention backbone, with mature clinical evidence and entrenched guideline use.
• Clinical “updates” tend to be comparative, safety, and implementation studies rather than new efficacy breakthroughs.
• Market growth is constrained by generic price compression and backbone substitution risk from TAF and alternate PrEP modalities.
• Projections should treat unit growth as modest and revenue growth as flat to low single-digit, with upside/downside driven by formulary and procurement outcomes.
• The near-term battleground is market access and persistence (program continuation), not patent-driven innovation.

FAQs

1) Is FTC/TDF still recommended for PrEP in major guidelines?

Yes in many settings, particularly where cost and formulary access favor TDF-based prevention. Adoption varies by geography and payer policy.

2) What most threatens FTC/TDF share in prevention?

Switching to TAF-based regimens and rollout of alternative prevention strategies that reduce reliance on daily oral dosing in certain markets.

3) Does FTC/TDF face safety-driven demand pullback?

Renal safety and monitoring burden are key factors; payer protocols that favor reduced monitoring can accelerate switching, especially in insured populations.

4) How do generics change the revenue outlook for FTC/TDF?

Generics compress price (ASP) over time; revenue growth is more likely to track volume than price, and flat-to-decline revenue can occur even when units rise.

5) What is the most actionable forecast variable for FTC/TDF businesses?

Tender and formulary outcomes for PrEP and NRTI backbone selection, including switching rates between TDF and TAF platforms.

---

References

[1] WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organization.
[2] CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States 2021 update: a clinical practice guideline. Centers for Disease Control and Prevention.
[3] UNAIDS. Global HIV & AIDS statistics. Joint United Nations Programme on HIV/AIDS.
[4] DHHS (NIH). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. U.S. Department of Health and Human Services.
[5] DrugBank. Emtricitabine and tenofovir disoproxil fumarate (combination). DrugBank.